Babies Exposed to Cannabis in the Womb Had Similar Health Outcomes at Age 2-3

Among 4,270 Medicaid-insured infants with meconium drug screening, cannabis-exposed infants (n=1,671) had similar rates of well-child care attendance, emergency department visits, and developmental delay diagnoses at 3 years compared to unexposed infants (n=2,599). At 2 years, cannabis-exposed infants actually had lower odds of developmental delay, though this difference disappeared by year 3.

Retrospective cohort linking meconium drug screen results from a university hospital (2014-2022) with North Carolina Medicaid claims. Cannabis-exposed infants (positive for cannabis only) were compared to substance-unexposed infants using regression models.

This is one of the largest studies using objective exposure measurement (meconium testing) rather than self-report. The null findings at 3 years are reassuring but do not rule out longer-term effects that may emerge later in childhood.

While these short-term findings are encouraging, they do not address potential effects on cognitive development, behavior, or academic performance that may only become apparent at school age. The study adds important data to the ongoing debate about prenatal cannabis exposure.

Only Medicaid-insured infants, who may differ from privately insured populations. Meconium screening only detects third-trimester exposure and cannot quantify amount used. Developmental delay diagnosed via claims codes may miss subtle delays. Follow-up limited to 3 years.